Nature Communications (Feb 2017)
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
- Moritz Schütte,
- Thomas Risch,
- Nilofar Abdavi-Azar,
- Karsten Boehnke,
- Dirk Schumacher,
- Marlen Keil,
- Reha Yildiriman,
- Christine Jandrasits,
- Tatiana Borodina,
- Vyacheslav Amstislavskiy,
- Catherine L. Worth,
- Caroline Schweiger,
- Sandra Liebs,
- Martin Lange,
- Hans- Jörg Warnatz,
- Lee M. Butcher,
- James E. Barrett,
- Marc Sultan,
- Christoph Wierling,
- Nicole Golob-Schwarzl,
- Sigurd Lax,
- Stefan Uranitsch,
- Michael Becker,
- Yvonne Welte,
- Joseph Lewis Regan,
- Maxine Silvestrov,
- Inge Kehler,
- Alberto Fusi,
- Thomas Kessler,
- Ralf Herwig,
- Ulf Landegren,
- Dirk Wienke,
- Mats Nilsson,
- Juan A. Velasco,
- Pilar Garin-Chesa,
- Christoph Reinhard,
- Stephan Beck,
- Reinhold Schäfer,
- Christian R. A. Regenbrecht,
- David Henderson,
- Bodo Lange,
- Johannes Haybaeck,
- Ulrich Keilholz,
- Jens Hoffmann,
- Hans Lehrach,
- Marie-Laure Yaspo
Affiliations
- Moritz Schütte
- Alacris Theranostics GmbH
- Thomas Risch
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Nilofar Abdavi-Azar
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Karsten Boehnke
- Eli Lilly and Company, Lilly Research Laboratories, Quantitative Biology
- Dirk Schumacher
- Charité–Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology
- Marlen Keil
- Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO)
- Reha Yildiriman
- Alacris Theranostics GmbH
- Christine Jandrasits
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Tatiana Borodina
- Alacris Theranostics GmbH
- Vyacheslav Amstislavskiy
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Catherine L. Worth
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Caroline Schweiger
- Institute of Pathology, Medical University of Graz
- Sandra Liebs
- Charité-Universitätsmedizin, Charitéplatz 1
- Martin Lange
- Bayer Pharma AG, Müllerstraße 178
- Hans- Jörg Warnatz
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Lee M. Butcher
- UCL Cancer Institute, University College London
- James E. Barrett
- UCL Cancer Institute, University College London
- Marc Sultan
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- Christoph Wierling
- Alacris Theranostics GmbH
- Nicole Golob-Schwarzl
- Institute of Pathology, Medical University of Graz
- Sigurd Lax
- Department of Pathology, Hospital Graz Süd-West
- Stefan Uranitsch
- Department of Surgery, Hospital Brothers of Charity Graz
- Michael Becker
- Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO)
- Yvonne Welte
- Charité–Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology
- Joseph Lewis Regan
- Bayer Pharma AG, Müllerstraße 178
- Maxine Silvestrov
- Charité–Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology
- Inge Kehler
- Charité-Universitätsmedizin, Charitéplatz 1
- Alberto Fusi
- Charité-Universitätsmedizin, Charitéplatz 1
- Thomas Kessler
- Alacris Theranostics GmbH
- Ralf Herwig
- Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics
- Ulf Landegren
- Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University
- Dirk Wienke
- Merck KGaA
- Mats Nilsson
- Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University
- Juan A. Velasco
- Eli Lilly and Company, Lilly Research Laboratories, Quantitative Biology
- Pilar Garin-Chesa
- Boehringer Ingelheim RCV GmbH & Co KG
- Christoph Reinhard
- Eli Lilly and Company, Lilly Research Laboratories, Oncology Translational Research, Lilly Corporate Center
- Stephan Beck
- UCL Cancer Institute, University College London
- Reinhold Schäfer
- Charité–Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology
- Christian R. A. Regenbrecht
- Charité–Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology
- David Henderson
- Bayer Pharma AG, Global External Innovation & Alliances
- Bodo Lange
- Alacris Theranostics GmbH
- Johannes Haybaeck
- Institute of Pathology, Medical University of Graz
- Ulrich Keilholz
- Charité-Universitätsmedizin, Charitéplatz 1
- Jens Hoffmann
- Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO)
- Hans Lehrach
- Alacris Theranostics GmbH
- Marie-Laure Yaspo
- Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Max Planck Institute for Molecular Genetics
- DOI
- https://doi.org/10.1038/ncomms14262
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 19
Abstract
The heterogeneity of colorectal cancer has important clinical and therapeutic implications. Here the authors analysed the responses of a large biobank of organoids and xenografts derived from colorectal patients to a panel of clinically relevant therapeutic agents to identify genes signatures associated with drug response.
